SGLT2抑制剂增加社区及住院期间糖尿病酮症酸中毒风险
该回顾性多中心对照队列研究纳入澳大利亚墨尔本和吉朗所有公立医院2015年9月至2017年10月连续发生的2型糖尿病DKA病例,比较SGLT2i使用者与非使用者的DKA发生率及住院期间发生风险。结果显示SGLT2i使用者住院期间发生DKA的OR为37.4,总体DKA发生率轻度但显著升高,且41%的SGLT2i使用者DKA时血糖峰值<250 mg/dL。
要点
- SGLT2i使用者住院期间发生DKA的风险显著高于非使用者(OR 37.4)。
- SGLT2i使用者DKA总体发生率轻度但显著增加(OR 1.48)。
- SGLT2i相关DKA常表现为血糖正常或轻度升高(<250 mg/dL)。
核心结论
- SGLT2i使用者较非使用者更易在住院期间发生DKA,且SGLT2i使用与DKA风险轻度但显著增加相关。
研究设计与样本
- 回顾性、多中心、对照队列研究,纳入澳大利亚墨尔本和吉朗所有公立医院2015年9月1日至2017年10月31日连续发生的2型糖尿病DKA病例。
主要发现
- 共162例DKA,其中SGLT2i使用者37例,非使用者125例。
- 住院期间发生DKA:SGLT2i使用者14例(38%),非使用者2例(2%),OR 37.4(95%CI 8.0-175.9),P<0.0001。
- DKA发生率:SGLT2i使用者1.02/1000(95%CI 0.74-1.41),非使用者0.69/1000(95%CI 0.58-0.82),OR 1.48(95%CI 1.02-2.15),P=0.037。
- SGLT2i使用者中15例(41%)血糖峰值<250 mg/dL(14 mmol/L),非使用者中1例(0.8%),P<0.001。
临床怎么用
- 对使用SGLT2i的2型糖尿病患者应警惕DKA风险,尤其在住院期间。
- SGLT2i相关DKA可无显著高血糖,需结合酮体检测避免漏诊。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Diabetic ketoacidosis (DKA) has been associated with the use of sodium glucose cotransporter 2 inhibitors (SGLT2is). OBJECTIVE: To determine the incidence, characteristics, and outcomes of DKA in SGLT2i users vs nonusers with type 2 diabetes. DESIGN: Retrospective, multicenter, controlled cohort study. SETTING: All public hospitals in Melbourne and Geelong (combined population of 5 million), Australia, from 1 September 2015 to 31 October 2017. PATIENTS: Consecutive cases of DKA that developed in the community, or during the course of hospital admission, in patients with type 2 diabetes. MAIN OUTCOME MEASURES: In SGLT2i users vs nonusers: (i) OR of DKA developing during hospital admission, and (ii) incidence of DKA. RESULTS: There were 162 cases of DKA (37 SGLT2i users and 125 non-SGLT2i users) with a physician-adjudicated diagnosis of type 2 diabetes. Of these, DKA developed during the course of inpatient admission in 14 (38%) SGLT2i users vs 2 (2%) non-SGLT2i users (OR, 37.4; 95% CI, 8.0 to 175.9; P < 0.0001). The incidence of DKA was 1.02 per 1000 (95% CI, 0.74 to 1.41 per 1000) in SGLT2i users vs 0.69 per 1000 (95% CI, 0.58 to 0.82 per 1000) in non-SGLT2i users (OR, 1.48; 95% CI, 1.02 to 2.15; P = 0.037). Fifteen SGLT2i users (41%) had peak blood glucose <250 mg/dL (14 mmol/L) compared with one (0.8%) non-SGLT2i user (P < 0.001). CONCLUSIONS: SGLT2i users were more likely to develop DKA as an inpatient compared with non-SGLT2i users. SGLT2i use was associated with a small but significant increased risk of DKA.
引用
- Hamblin PS, Wong R, Ekinci EI, et al. SGLT2 Inhibitors Increase the Risk of Diabetic Ketoacidosis Developing in the Community and During Hospital Admission. J Clin Endocrinol Metab. 2019. PMID: 30835263. doi:10.1210/jc.2019-00139
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。